StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Oppenheimer Reiterates Perform Rating on Acadia Pharmaceuticals (ACAD)
September 23, 2026 5:24 AM
Oppenheimer analyst Matthew Hershenhorn reiterated a Perform rating and $25.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments "We ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
